Åsa Wallin
31 – 40 of 56
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2012
-
Mark
Alzheimer’s disease with normal CSF biomarkers.
2012) 12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy(
- Contribution to conference › Poster
- 2011
-
Mark
Long-term Outcome and Prediction Models of Activities of Daily Living in Alzheimer Disease With Cholinesterase Inhibitor Treatment.
(
- Contribution to journal › Article
-
Mark
Risk Factors for Nursing Home Placement in Alzheimer's Disease: A Longitudinal Study of Cognition, ADL, Service Utilization, and Cholinesterase Inhibitor Treatment.
(
- Contribution to journal › Article
-
Mark
Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting.
(
- Contribution to journal › Article
-
Mark
Predictors of long-term cognitive outcome in Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
The long-term cognitive outcomes of Alzheimer’s disease — influence of APOE genotype, NSAID therapy, and cholinesterase inhibitor treatment.
2011) 10th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2011)(
- Contribution to conference › Poster
- 2010
-
Mark
The PSEN1 I143T mutation in a Swedish family with Alzheimer's disease: clinical report and quantification of A beta in different brain regions
(
- Contribution to journal › Article
-
Mark
CSF biomarkers predict a more malignant outcome in Alzheimer disease.
(
- Contribution to journal › Article
-
Mark
Plasma concentration of galantamine - influence of dose and body mass index in Alzheimer’s disease.
2010) 11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy(
- Contribution to conference › Poster
- 2009
-
Mark
Long-term rivastigmine treatment in a routine clinical setting.
(
- Contribution to journal › Article